StockData
Assembly Biosciences, Inc. logo

Assembly Biosciences, Inc. (ASMB) stock

ASMBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 12/309% below fair value
$22.39−0.11 (-0.49%)

Close on Nov 18, 2026Market cap $455.87MP/E –Yield –

Assembly Biosciences operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Assembly Biosciences's operating income for the twelve months ending Jun 30, 2026 was -$8.80M. For fiscal 2025 it was -$12.12M. The highest annual figure on record is -$3.34M in fiscal 2009.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$12.12M–
FY2024Dec 31, 2024-$45.42M–
FY2023Dec 31, 2023-$64.65M–
FY2022Dec 31, 2022-$94.11M–
FY2021Dec 31, 2021-$132.69M–
FY2020Dec 31, 2020-$64.78M–
FY2019Dec 31, 2019-$102.71M–
FY2018Dec 31, 2018-$92.74M–
FY2017Dec 31, 2017-$52.23M–
FY2016Dec 31, 2016-$45.28M–
FY2015Dec 31, 2015-$29.66M–
FY2014Dec 31, 2014-$23.96M–
FY2013Dec 31, 2013-$19.60M–
FY2012Dec 31, 2012-$24.86M–
FY2011Dec 31, 2011-$34.00M–
FY2010Dec 31, 2010-$4.77M–
FY2009Dec 31, 2009-$3.34M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$6.34M–
Q1 FY2026Mar 31, 2026-$11.37M–
Q4 FY2025Dec 31, 2025$19.80M–
Q3 FY2025Sep 30, 2025-$10.88M–
Q2 FY2025Jun 30, 2025-$11.09M–
Q1 FY2025Mar 31, 2025-$9.94M–
Q4 FY2024Dec 31, 2024-$11.53M–
Q3 FY2024Sep 30, 2024-$10.96M–
Q2 FY2024Jun 30, 2024-$12.20M–
Q1 FY2024Mar 31, 2024-$10.73M–
Q4 FY2023Dec 31, 2023-$12.55M–
Q3 FY2023Sep 30, 2023-$15.05M–
Q2 FY2023Jun 30, 2023-$17.49M–
Q1 FY2023Mar 31, 2023-$19.56M–
Q4 FY2022Dec 31, 2022-$22.98M–
Q3 FY2022Sep 30, 2022-$23.40M–
Q2 FY2022Jun 30, 2022-$24.57M–
Q1 FY2022Mar 31, 2022-$23.16M–
Q4 FY2021Dec 31, 2021-$62.89M–
Q3 FY2021Sep 30, 2021-$18.88M–
Q2 FY2021Jun 30, 2021-$23.67M-459.7%
Q1 FY2021Mar 31, 2021-$27.26M–
Q4 FY2020Dec 31, 2020-$39.64M–
Q3 FY2020Sep 30, 2020-$4.02M–
Q2 FY2020Jun 30, 2020$6.58M–
Q1 FY2020Mar 31, 2020-$27.69M–
Q4 FY2019Dec 31, 2019-$28.68M–
Q3 FY2019Sep 30, 2019-$25.99M–
Q2 FY2019Jun 30, 2019-$19.70M–
Q1 FY2019Mar 31, 2019-$28.34M–
Q4 FY2018Dec 31, 2018-$26.32M–
Q3 FY2018Sep 30, 2018-$22.58M–
Q2 FY2018Jun 30, 2018-$27.17M–
Q1 FY2018Mar 31, 2018-$16.67M–
Q4 FY2017Dec 31, 2017-$12.28M–
Q3 FY2017Sep 30, 2017-$12.45M–
Q2 FY2017Jun 30, 2017-$13.57M–
Q1 FY2017Mar 31, 2017-$13.93M–
Q4 FY2016Dec 31, 2016-$11.87M–
Q3 FY2016Sep 30, 2016-$11.68M–

More Assembly Biosciences figures

See a number that looks wrong?